Research programme: CEL 1000 - CEL-SCI

Drug Profile

Research programme: CEL 1000 - CEL-SCI

Alternative Names: CEL 1000; CEL-1000 peptide; derG; DGQEEKAGVVSTGLIGGG

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator CEL-SCI Corporation
  • Developer CEL-SCI Corporation; National Institute of Allergy and Infectious Diseases; Naval Medical Research Center; United States Army Medical Research Institute of Infectious Diseases; University of Arkansas System; University of Nebraska Medical Center
  • Class Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Encephalitis virus infections; Hepatitis B; Herpes simplex virus infections; Influenza A virus H5N1 subtype; Malaria; Severe acute respiratory syndrome; Smallpox; Vaccinia; West Nile virus infections
  • Discontinued Chlamydial infections

Most Recent Events

  • 27 Apr 2009 Pharmacodynamics data from an in vitro trial released by CEL-SCI Corporation
  • 05 Mar 2008 Preclinical development is ongoing
  • 03 May 2007 Preclinical trials in Hepatitis B in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top